Peptide Half-Life Chart
Approximate half-life values for common research peptides as reported in published preclinical literature. Use these values to inform research timing protocols and dosing frequency schedules.
Half-life values listed here are approximations from published preclinical research (rodent/animal models) and may vary based on route of administration, reconstitution concentration, storage conditions, and research model. SC = subcutaneous; IP = intraperitoneal; IV = intravenous — all routes refer to animal model administration only. This information is for laboratory reference only — not medical advice. Not for human use.
What Is Half-Life?
A peptide's half-life is the time it takes for the concentration of an active compound to reduce by 50% in a given biological system. It is a key pharmacokinetic parameter used by researchers to determine how frequently a compound needs to be administered to maintain consistent activity in a research model. Shorter half-lives generally require more frequent dosing, while longer half-lives allow for less frequent administration.
Half-life values in peptide research are typically affected by the route of administration (subcutaneous vs. intraperitoneal vs. intravenous), the biological matrix, and whether the peptide has been modified for stability.
Half-Life Reference Chart
| Compound | Category | Approx. Half-Life | Published Route (Preclinical Models) | Notes |
|---|---|---|---|---|
| BPC-157 | Repair Peptide | ~4 hours | SC / IP | Stable in gastric juice; values from rodent preclinical models |
| Tesamorelin | GHRH Analog | ~26–38 minutes | SC | Longer than native GHRH due to trans-3-hexenoic acid modification; values from rodent preclinical models |
| GLP-3RT (Retatrutide) | GLP-1/GIP/Glucagon Agonist | ~6 days | SC | Long-acting; C18 fatty acid conjugation for albumin binding; values from published preclinical studies |
| GLU-600 | Metabolic Peptide | Research-specific | SC | Refer to compound-specific protocol |
| GLOW | Multi-Peptide Blend | Blend-dependent | SC | Half-life reflects individual components |
Why Half-Life Matters in Research
Understanding half-life helps researchers design protocols with appropriate administration frequency for their research model. For example, Tesamorelin has a short half-life of ~26–38 minutes, making once-daily administration common in published preclinical research. In contrast, GLP-3RT with its ~6-day half-life is typically studied with once-weekly administration schedules in published preclinical studies.
When designing a multi-compound research protocol, account for the combined effects of different half-lives and overlap periods. Use the Peptide Dosage Chart in conjunction with these half-life values for complete protocol planning.
Half-Life vs. Storage Stability
Half-life should not be confused with storage stability. A peptide may have a short in vivo half-life but remain stable in a refrigerated reconstituted vial for 28–60 days. For complete storage guidance, see the Peptide Storage Guide. Once reconstituted, use the reconstitution protocol to ensure proper preparation and maximum stability.
Shop Research Compounds
All compounds available at alphatideshop.com — third-party tested, USA based.